肿瘤预防与治疗2025，Vol.38Issue(1)：33-41,9.DOI:10.3969/j.issn.1674-0904.2025.01.005
阿比特龙治疗前列腺癌的疗效和安全性的meta分析
Efficacy and Safety of Abiraterone in the Treatment of Prostate Cancer:A Meta-Analysis
摘要
Abstract
Objective:To systematically evaluate the efficacy and safety of abiraterone in the treatment of prostate cancer.Methods:We comprehensively searched Pubmed,WanFang Data,ClinicalTrials,CNKI,Embase and other Chinese and English databases,and collected the RCT studies on abiraterone in the treatment of prostate cancer published up until August 2023.Effective data related to efficacy and safety were extracted from studies that met the inclusion require-ments,and meta-analysis was performed using RevMan5.3 software.Progression-free survival(PFS),prostate-specific antigen(PSA)level,effective rate,PSA response rate,and ad-verse reaction rate were compared between the abiraterone group and control group.Results:6,439 cases from 10 studies were included.The results of meta-analysis showed that the abiraterone group was longer in PFS than the control group(SMD=1.975,95％CI:1.505～2.445,Z=8.240,P＜0.001);the level of PSA in the abiraterone group was lower than that in control group(SMD=-1.283,95％CI:-2.120～-0.446,Z=3.000,P=0.003);the effective rate and PSA response rate in the abiraterone group were higher than those in control group(OR=3.724,95％CI:3.080～4.503,Z=13.570,P＜0.001;OR=3.099,95％CI:1.380～6.962,Z=2.740,P=0.006);the adverse reaction rate in the abiraterone group was lower than that in control group(OR=0.356,95％CI:0.187～0.678,Z=3.140,P=0.002).Conclusion:Abiraterone is effec-tive and safe in the treatment of prostate cancer,it can effectively prevent the progression of castration-resistant prostate canc-er,prolong the survival time of patients and significantly reduce adverse reactions.关键词
阿比特龙/前列腺癌/疗效/Meta分析/安全性Key words
Abiraterone/Prostate cancer/Efficacy/Meta-analysis/Safety分类
医药卫生引用本文复制引用
雷乃军,谭政,李曾,祝德,张军旗..阿比特龙治疗前列腺癌的疗效和安全性的meta分析[J].肿瘤预防与治疗,2025,38(1):33-41,9.基金项目
This study was supported by grants from Science and Technology Department of Sichuan Province(No.2020YFS0421). 四川省科技厅重点研发计划项目(编号:2020YFS0421) （No.2020YFS0421）
